Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Welcome to Q2 ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(450)
•••
Comment by davgroon Apr 11, 2022 1:41pm
132 Views
Post# 34594301

RE:RE:RE:RE:Welcome to Q2 ...

RE:RE:RE:RE:Welcome to Q2 ...
WalterWheat21 wrote: Just for you dusty. Magic posted it earlier. You try to credit as if you have something to offer. You add zero value to board, and stoop pathetic antagonization over entry prices. You are indeed a goof. Pretty sure most people put you on iggy, as they should.

You need to understand that the Dust Pan is just an internet troll.  He truly adds zero value to all the boards he posts on.  If you need verification of that just check his past posts in his profile.  His negativity is a result of all the losses he has taken in the market especially with his prize cannabis stock Vibe. Its share price has dropped like a brick while he kept trying to catch the falling knife and bought more shares all the way down.  It now sits near its 52-week low with zero trading interest in the stock.

Dust Pan or Asshat as I like to call him, fancies himself a day trader which is laughable since he works the drive through at MacDonalds and lives in his mom's basement.  I personally trade over $100K daily while he flips his pennies in hopes of a $50 profit.   I had him on ignore but now I enjoy reading his childish posts with YouTube memes.  His behavior is truly sad, bordering on pathetic but I have seen 100s of trolls like him after 22 years as a member of Stockhouse.  The best way to silence trolls like him is not to respond to his posts.  He thrives on that attention to pump up his ego since his life is truly miserable.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities